MABPHARM-B (02181) Company Profile - Company Info, Industry & Management

返回 Overview News Financials Shareholders Profile IPO ›

Industry

Innovative Drugs & Biologics 0.02%

124 stocks in this industry

3 >7%

3 5~7%

10 3~5%

36 0~3%

15 0%

38 0~3%

13 3~5%

1 5~7%

5 >7%

Down 52 Up 57

Industry RankingsValue (HKD)Rank

Revenue (Last FY)757.65M62/112

Net Profit (Last FY)67.00M49/125

ROE (Last FY)36.32%4/117

Change is the 2026-10-09 close against the previous close; the industry change is the equal-weighted average of its stocks. Sub-industry classification is maintained by cibo. Last FY is each company's latest annual report. Net profit is profit attributable to owners of the parent; ROE = net profit / closing equity attributable to owners. Non-HKD statements are converted at ECB reference rates.

Management

NamePosition

Wang Hao Executive Director

Li Yunfeng Executive Director

Tao Jing Executive Director

Hou Sheng Executive Director

Qian Weizhu Executive Director

Jiao Shuge Non-Executive Director

Cen Jialin Non-Executive Director

Zhang Yanyun Independent Non-Executive Director

Guo Liangzhong Independent Non-Executive Director

Leung, Louis Ho Ming Independent Non-Executive Director

Tao Qian Independent Non-Executive Director

Board list from the HKEXnews "List of Directors and their Role and Function", as of 2025-10-31.

About this page

This page shows MABPHARM-B (02181) company information, related securities, the price change distribution and in-industry rankings within its sub-industry, and the board of directors. Quotes come from HKEX Daily Quotations, financial metrics from each company's latest annual report, and the director list from HKEXnews.

MABPHARM-B 02181

Company Information

Industry

Management

MABPHARM-B 02181·

Company Information

Industry

Management

MABPHARM-B 02181